Skip to main content

Advertisement

SpringerLink
Log in

Intravenous Vasodilator Therapy in Congestive Heart Failure

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The prevalence of congestive heart failure (CHF) is increasing in the US and worldwide, partly because patients are living longer. Treatment of CHF is mostly on an outpatient basis, but inpatient care is required for decompensated CHF, acute CHF or poor response to outpatient treatment. Control of symptoms is usually achieved by diuresis.

Intravenous (IV) vasodilators are an important adjunct to the inpatient treatment of CHF. They work mainly by reducing the afterload on the myocardium although preload reduction also occurs. After clinical stabilisation, the goal is to switch to a maintenance oral regimen to be continued as outpatient therapy. The range of IV vasodilators available for inpatient treatment of CHF includes nitrates, phosphodiesterase inhibitors, dobutamine, morphine, ACE inhibitors, B-type natriuretic peptides and endothelin receptor antagonists. As each agent may have a different mechanism or site of action, each agent may affect preload, contractility or afterload to a different extent and it may be desirable to choose one over the other in a particular clinical setting.

Examples of standard therapy include dobutamine, milrinone and nitroglycerin. Nesiritide, a B-type natriuretic peptide, is a newer vasodilator and US FDA approved for use in acute CHF. However, most studies with this agent have been in small numbers of patients with anecdotal findings. Larger studies are warranted to pinpoint the efficacy and adverse effects of this agent. It is primarily used to reduce the acuity of decompensated CHF on admission to hospital.

Endothelin receptor antagonists show promise in the management of acute CHF, but continue to be investigational. Long-term data on their efficacy and safety are limited. None of the endothelin receptor antagonists are FDA approved for use in patients with CHF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention: National Vital Statistics Report, vol 47. Hyattsville (MD): Natoinal Center for Health Statistics, 1999

  2. Murrell W. Nitroglycerin as a remedy for angina pectoris [letter]. Lancet 1979; I: 80

    Google Scholar 

  3. Christenson B, Nordenfelt I, Westling H, et al. Intravenous infusion of nitroglycerin in normal subjects [abstract]. Scand J Clin Lab Invest 1969; 23: 49–53

    Article  Google Scholar 

  4. Miller RR, Vismara LA, Williams DO, et al. Pharmocologic mechanism for left ventricular unloading in clinical congestive heart failure: differential effects of nitroprusside, phentolamin, and nitroglycerin on cardiac function and peripheral circulation. Circ Res 1976; 39: 127–33

    Article  PubMed  CAS  Google Scholar 

  5. Braunwald E, Zipes DP, Libby P. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia (PA): WB Saunders Company, 2001

    Google Scholar 

  6. Braunwald E, Fauci AS, Kasper DL, et al. Harrison’s principles of internal medicine. 15th ed. New York: McGraw-Hill Professional, 2001

    Google Scholar 

  7. Goldman L, Bennett JC. Cecil textbook of medicine. 21st ed. Philadelphia (PA): WB Saunders Company, 2000

    Google Scholar 

  8. Mikolich JR, Nicoloff NB, Robinson PH, et al. Relief of refratory angina with continous Infusion of nitroglycerin. Chest 1980; 77: 375–9

    Article  PubMed  CAS  Google Scholar 

  9. Kovick RB, Tillisch JH, Berens SC, et al. Vasodilator therapy for chronic left ventricular failure. Circulation 1976; 53: 322–8

    Article  PubMed  CAS  Google Scholar 

  10. Stengert KB, Wilsey BL, Hurley EJ, et al. Incremental intravenous nitroglycerin for control of afterload during anesthesia in patients undergoing myocardial revascularization. Anesthetist 1978; 27: 223–7

    CAS  Google Scholar 

  11. Greenberg H, Dwyer EM, Jameson AG, et al. Effects of nitroglycerin on the major determinants of myocardial oxygen consumption. Am J Cardiol 1975; 36: 426–32

    Article  PubMed  CAS  Google Scholar 

  12. Honig CR, Tenny SM, Gable PV. The mechanism cardiovascular action of nitroglycerin. AM J Med 1960; 29: 910–23

    Article  PubMed  CAS  Google Scholar 

  13. Vyden JK, Carvalho M, Boszormenyi, et al. Effects of glyceryl trinitrate (Nitroglycerin) on the systemic and coronary circulation of the dog. Am J Cardiol 1970; 25: 53–8

    Article  PubMed  CAS  Google Scholar 

  14. Herling IM. Intravenous nitroglycerin: clinical pharmacology and therapeutic considerations. Am Heart J 1984; 108: 141–8

    Article  PubMed  CAS  Google Scholar 

  15. Cohen MV, Downey JM, Sonnenblick EH, et al. The effects of nitroglycerine on coronary collaterals and myocardial contractility. J Clin Invest 1973; 52: 2836–47

    Article  PubMed  CAS  Google Scholar 

  16. Malondzak GS, Green HO, Sragg PL. Effects of nitroglycerin on flow after partial constriction of the coronary artery. J Appl Physiol 1970; 29: 17–22

    Google Scholar 

  17. DeMaria AN, Vismara LA, Auditore K, et al. Effects of nitroglycerin on left ventricular cavity size and cardiac performance determined by ultrasound in man. Am J Med 1974; 57: 754–60

    Article  PubMed  CAS  Google Scholar 

  18. Stinson EB, Holloway EL, Derby G, et al. Comparative homodynamic responses to chlorpromazin, nitroprusside, nitroglycerin, and trimethaphan immediately after open heart surgery operations. Circulation 1975; Suppl. 51–52: 26–33

    Google Scholar 

  19. Kotter V, Von Leitner ER, Wundeerlich J, et al. Comparison of hemodynamic effects of Phentolamin, sodium nitroprusside, and glyceryl nitrate in acute myocardial infarction. Br Heart J 1977; 39: 1196–204

    Article  PubMed  CAS  Google Scholar 

  20. Horwitz LD, Gorlin R, Taylor WJ, et al. Effects of nitroglycerin on regional myocardial blood flow in coronary artery disease. J Clin Invest 1971; 50: 1578–84

    Article  PubMed  CAS  Google Scholar 

  21. Moir TW. Subendocardial distribution of coronary blood flow and the effect of antianginal drugs. Circ Res 1972; 30: 621–7

    Article  PubMed  CAS  Google Scholar 

  22. Knoebel SB, McHenry PL, Bonner AJ, et al. Myocardial blood flow in coronary artery disease: effects of right arterial pacing and nitroglycerin. Circulation 1973; 47: 690–6

    Article  PubMed  CAS  Google Scholar 

  23. Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999; 99(1): 168–77

    Article  PubMed  CAS  Google Scholar 

  24. Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 1998; 31: 83–8

    Article  PubMed  CAS  Google Scholar 

  25. Parker JO, Parker JD. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am J Cardiol 1992; 70: 93B–7B

    Article  PubMed  CAS  Google Scholar 

  26. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998; 338: 520–31

    Article  PubMed  CAS  Google Scholar 

  27. Maxwell SRJ, Kendall MJ. An update on nitrate tolerance: can it be avoided? Postgrad Med J 1992; 68: 857–66

    Article  PubMed  CAS  Google Scholar 

  28. Kowaluk EA, Seth P, Fung HL. Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. J Pharmacol Exp Ther 1992; 262: 916–22

    PubMed  CAS  Google Scholar 

  29. Silverstein PR, Caldera DL, Cullen DJ, et al. Avoiding the hemodynamic consequences of aortic cross-clamping and unclamping. Anesthesiology 1979; 50: 462–6

    Article  PubMed  CAS  Google Scholar 

  30. Kaplan JL, Jones EL. Vasodilator therapy during coronary artery surgery: comparison of nitroglycerin and nitroprusside. J Thorac Cardiovasc Surg 1979; 77: 301–9

    PubMed  CAS  Google Scholar 

  31. Flaherty JT, Magee PA, Gardner TL, et al. Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute hypertension developing after coronary artery bypass surgery. Circulation 1982; 65(6): 1072–7

    Article  PubMed  CAS  Google Scholar 

  32. Tobias MA. Comparison of nitroprusside and nitroglycerin for controlling hypertension during coronary artery surgery. Br J Anaesth 1981; 53: 891–7

    Article  PubMed  CAS  Google Scholar 

  33. Durrer JD, Lie KI, VanCapell FJL, et al. Effect of sodium nitroprusside on mortality in acute myocardial infarction. N Engl J Med 1982; 306: 1121–8

    Article  PubMed  CAS  Google Scholar 

  34. Cohn JN, Franciosca JA, Francis GS, et al. Effects of short term infusion of sodium nitroprusside on morality rate in acute myocardial infarction complicated by left ventricular infarction. N Engl J Med 1982; 306: 1129–35

    Article  PubMed  CAS  Google Scholar 

  35. Mann T, Cohn PF, Holman BL, et al. Effects of nitroprusside on regional myocardial blood flow in coronary disease: results in 25 patients and comparison with nitroglycerine [abstract]. Circulation 1978; 57: 732

    Article  PubMed  CAS  Google Scholar 

  36. Cappuro NL, Kent KM, Epstein SE. Comparison of nitroglycerine, nitroprusside on intramural cabon dioxide tension during acute experimental myocardial ischemia in dogs. Circ Res 1981; 48: 372–8

    Article  Google Scholar 

  37. Lukes SA, Calixto A, Romero JR, et al. Haemodynamic effects of sodium nitroprusside in 21 subjects with congestive heart failure. Br Heart J 1979; 41: 187–91

    Article  PubMed  CAS  Google Scholar 

  38. Wood M, Hyman S, Wood AJ. A clinical study of sensitivity to sodium nitroprusside during controlled hypotension in young and elderly patients. Anesth Analg 1987; 66: 132–6

    Article  PubMed  CAS  Google Scholar 

  39. Naccarelli GV, Goldstein RA. Electrophysiology of phosphodiesterse inhibitors. Am J Cardiol 1989; 63(2): 35A–40A

    Article  PubMed  CAS  Google Scholar 

  40. Kondo N, Shibata S, Kosama I, et al. Electrical and mechanical effects of inamrinone on isolated guinea pig ventricular muscle. J Cardiovasc Pharm 1983; 5: 903–12

    Article  CAS  Google Scholar 

  41. Rending SV, Amsterdam EA. Positive inotropic action of inamrinone: effect of elevated external Ca2+. J Cardiovasc Pharm 1984; 6: 293–9

    Article  Google Scholar 

  42. Wynne J, Malacoff RF, Benotti JR, et al. Oral inamrinone in refractory congestive heart failure. Am J Cardiol 1980; 45: 1245–9

    Article  PubMed  CAS  Google Scholar 

  43. Wilmhurst PT, Thompson DS, Jenkins BS, et al. Haemodynamic effects of intravenous inamrinone in patients with impaires left ventricular function. Br Heart J 1983; 49: 77–82

    Article  Google Scholar 

  44. Wilmhurst PT, Thompson DS, Juul SM, et al. Comparison of effects of inamrinone and sodium nitroprusside on hemodynamics, contractility and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. Br Heart J 1984; 52: 38–48

    Article  Google Scholar 

  45. Franciosa JA. Intravenous inamrinone: an advance or a wrong step? Ann Intern Med 1985; 102: 399–400

    PubMed  CAS  Google Scholar 

  46. Firth B, Ratner AV, Grassman ED, et al. Assessment of inotropic and vasodilator effects of inamrinone versus isoproterenol. Am J Cardiol 1984; 54: 1331–6

    Article  PubMed  CAS  Google Scholar 

  47. Honerjager P, Schafer-Korting M, Reiter M. Involvement of cyclic AMP in the direct inotropic action of inamrinone: biomedical and functional evidence. Naunyn Schmiedebergs Arch Pharmacol 1981; 318: 112–20

    PubMed  CAS  Google Scholar 

  48. Siskind SJ, Sonnenblick EH, Forman R, et al. Acute substantial benefit of inotropic therapy with inamrinone on exercise hemodynamics and metabolism in sever congestive heart failure. Circulation 1981; 64: 966–73

    Article  PubMed  CAS  Google Scholar 

  49. LeJemtel TH, Keung E, Sonnenblick EH, et al. Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation 1979; 59: 1098–104

    Article  PubMed  CAS  Google Scholar 

  50. Inamrinone: summary basis of approval. Appendix VI. Sterling Drug INC, 1984 Jul

  51. Benotti JR, Grossman W, Braunwald E, et al. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 1980; 62: 28–34

    Article  PubMed  CAS  Google Scholar 

  52. Naccarelli GV, Gray EL, Dougherty AH, et al. Amrinone: acute electrophysiologic and hemodynamic effects in congestive heart failure. Am J Cardiol 1984; 54: 600–4

    Article  PubMed  CAS  Google Scholar 

  53. Treadway G. Clinical safety of intravenous amrinone: a review. Am J Cardiol 1985; 56: 39B–40B

    Article  PubMed  CAS  Google Scholar 

  54. Alouse AA, Canter JM, Montenaro MJ, et al. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983; 5: 792–803

    Article  Google Scholar 

  55. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med 1986; 314: 349–58

    Article  PubMed  CAS  Google Scholar 

  56. Arakawa Y, Kikuta K, Hojo M, et al. Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of 7 cases. Neurosurgery 2001; 48(4): 723–30

    PubMed  CAS  Google Scholar 

  57. Anon. Sterling drops oral milrinone development based on 27% mortality. FDC reports: Prescription and OTC Pharmaceuticals. The Pink Sheet 1990; 52: T&G4

  58. Sterling Winthrop Research Institute. A summary of laboratory and clinical data on Milrinone (Win 47203 cardiotonic). New York: Rensselaer, 1987 Sep 23

    Google Scholar 

  59. Baim DS, McDowell AV, Cherniles J, et al. Evaluation of a new bipyridine inotropic agent- milrinone- in patients with sever congestive heart failure. N Engl J Med 1983; 309: 748–56

    Article  PubMed  CAS  Google Scholar 

  60. Anderson JL, Baim DS, Fein SA, et al. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. J Am Coll Cardiol 1987; 9: 711–22

    Article  PubMed  CAS  Google Scholar 

  61. Kabela E, Barcenas L, Farah A. The effects of milrinone (Win 47203) on the coronary blood flow and oxygen consumption of the dog heart lung preparation. Am Heart J 1986; 111: 702–9

    Article  PubMed  CAS  Google Scholar 

  62. Colucci WS, Ludmer PL, Arnold JMO, et al. Myocardial and vascular actions of intracoronary versus intravenous milrinone. Trans Assoc Am Physicians 1985; 98: 136–45

    PubMed  CAS  Google Scholar 

  63. Monrad ES, McKay RG, Baim DS, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984; 70: 1030–7

    Article  PubMed  CAS  Google Scholar 

  64. Siegel LA, Keung E, Siskind SJ, et al. Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure. Circulation 1981; 63: 838–44

    Article  PubMed  CAS  Google Scholar 

  65. Monrad ES, Baim DS, Smith HS, et al. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 1985; 71: 972–9

    Article  PubMed  CAS  Google Scholar 

  66. Goldstein RA, Geraci SA, Gray EL, et al. Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 1986; 57: 624–8

    Article  PubMed  CAS  Google Scholar 

  67. Ramamoorthy C, Anderson GD, Williams GD, et al. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg 1998; 86: 283–9

    PubMed  CAS  Google Scholar 

  68. Anderson JL, Askins JC, Gilbert EM, et al. Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. Am Heart J 1986; 111: 466–74

    Article  PubMed  CAS  Google Scholar 

  69. Alhashemi JA, Hooper J. Treatment of milrinone-associated tachycardia with beta-blockers. Can J Anaesth 1998; 45: 67–70

    Article  PubMed  CAS  Google Scholar 

  70. Primacor® [prescribing information]. New York: Sanofi-Synthelabo Inc., 2000

  71. Larsson R, Liedholm H, Andersson KE, et al. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. Eur J Clin Pharmacol 1986; 29: 549–53

    Article  PubMed  CAS  Google Scholar 

  72. Ruffolo RR, Spradin TA, Pollock GD, et al. Alpha- and beta-adrenergic effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther 1981; 219: 447–52

    PubMed  CAS  Google Scholar 

  73. Ruffolo RR, Yaden EL. Vascular effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther 1983; 224: 46–50

    PubMed  CAS  Google Scholar 

  74. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975; 36: 185–96

    Article  PubMed  CAS  Google Scholar 

  75. Lumley P, Broadley KJ, Levy GP. Analysis of the inotropic: chronotropic selectivity of dobutamine and dopamine in anaesthetized dogs and guinea pig isolated atria. Cardiovasc Res 1977; 11: 17–25

    Article  PubMed  CAS  Google Scholar 

  76. Leier CV, Unverferth DV, Kates RE. Diagnosis and treatment: drugs five years later: dobutamine. Ann Intern Med 1983; 99: 490–6

    PubMed  CAS  Google Scholar 

  77. Robie NW, Nutter DO, Moody C, et al. In vivo analysis of adrenergic receptor activity of dobutamine. Circ Res 1974; 34: 663–71

    Article  PubMed  CAS  Google Scholar 

  78. Tuttle RR, Hillmann CC, Toomey RE. Differential beta adrenergic sensitivity of atrial and ventricular tissues assessed by chronotropic, inotropic, and cyclic AMP responses to isoprenaline and dobutamine. Cardiovasc Res 1976; 10: 452–8

    Article  PubMed  CAS  Google Scholar 

  79. Berkowitz C, McKeever L, Croke RP, et al. Comparative responses to dobutamine and nitroprusside in patients with chronic low output cardiac failure. Circulation 1977; 56: 917–24

    Article  Google Scholar 

  80. Jewitt D, Birkhead J, Mitchell A, et al. Cardiovascular effects of dobutamine, a selective inotropic catecholamine. Br Heart J 1974; 36: 1034–5

    PubMed  CAS  Google Scholar 

  81. Jewitt D, Birkhead J, Mitchell A, et al. Clinical cardiovascular pharmacology of dobutamine, a selective inotropic catecholamine. Lancet 1974; II: 363–7

    Article  Google Scholar 

  82. Leier CV, Heban P, Huss P, et al. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978; 58: 466–75

    Article  PubMed  CAS  Google Scholar 

  83. Leier CV, Webel J, Bush CA. The cardiovascular effects of continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977; 56: 468–72

    Article  PubMed  CAS  Google Scholar 

  84. Akhtar N, Esteban M, Cohn J, et al. Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol 1975; 36: 202–5

    Article  PubMed  CAS  Google Scholar 

  85. Amin DK, Shah PK, Shellock FG, et al. Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure. Am Heart J 1985; 109: 91–8

    Article  PubMed  CAS  Google Scholar 

  86. Meyer SL, Curry GC, Donsky MS, et al. Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease. Am J Cardiol 1976; 38: 103–8

    Article  PubMed  CAS  Google Scholar 

  87. Gillespie TA, Ambos HD, Sobel BE, et al. Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977; 39: 588–94

    Article  PubMed  CAS  Google Scholar 

  88. Smith RE, Briggs B, Unverferth DV, et al. Dobutamine-induced inhibition of platelet function. Int J Clin Pharm Res 1982; 2: 89–97

    CAS  Google Scholar 

  89. O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999; 138(1): 78–86

    Article  PubMed  Google Scholar 

  90. Rich MW, Imburgia M. Inotropic response to dobutamine in elderly patients with decompensated congestive heart failure. Am J Cardiol 1990; 65: 519–21

    Article  PubMed  CAS  Google Scholar 

  91. Unverferth DV, Blanford M, Kates RE, et al. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med 1980; 69: 262–6

    Article  PubMed  CAS  Google Scholar 

  92. Elis A, Bental T, Kimchi O, et al. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 1998; 63: 682–5

    Article  PubMed  CAS  Google Scholar 

  93. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999; 138: 247–53

    Article  PubMed  CAS  Google Scholar 

  94. Sacher HL, Sacher ML, Landau SW, et al. Outpatient dobutamine therapy: the rhyme and the riddle. J Clin Pharmacol 1992; 32: 141–7

    PubMed  CAS  Google Scholar 

  95. Miller LW, Merkle EJ, Herrmann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med 1990; 18: S30–3

    Article  PubMed  CAS  Google Scholar 

  96. Roffman DS, Applefeld MM, Grove WR, et al. Intermittent dobutamine hydrochloride infusions in outpatients with chronic congestive heart failure. Clin Pharm 1985; 4: 195–9

    PubMed  CAS  Google Scholar 

  97. Levine TB, Levine AB, Elliott WG, et al. Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure. Clin Cardiol 2001; 24: 231–6

    Article  PubMed  CAS  Google Scholar 

  98. Dukes MNG. Meyler’s side effects of drugs, Ann 3. New York: Excerpta Medica, 1979

    Google Scholar 

  99. Rabinovitch MA, Kalff V, Chan W, et al. The effect of dobutamine on exercise performance in patients with symptmatic ischemic heart disease. Am Heart J 1984; 107: 81–5

    Article  PubMed  CAS  Google Scholar 

  100. La Vecchia L, Ometto R, Finocchi G, et al. Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure. Pacing Clin Electrophysiol 1999; 22: 397–9

    Article  PubMed  CAS  Google Scholar 

  101. Renard M, Bernard R, Melot C, et al. Hemodynamic effects of dobutamine in patients below and over 65 years, with left heart failure secondary to an acute myocardial infarction. Gerentology 1984; 30: 408–13

    Article  CAS  Google Scholar 

  102. Wu CC, Chen WJ, Cheng JJ, et al. Local dermal hypersensitivity from dobutamine hydrochloride (Dobutrex solution) injection. Chest 1991; 99: 1547–8

    Article  PubMed  CAS  Google Scholar 

  103. Cepeda M. et al. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2001; 70(4): 351–61

    PubMed  CAS  Google Scholar 

  104. Rutter N, Evans N. Cardiovascular effects of an intravenous bolus of morphine in the ventilated preterm infant. Arch Dis Child Fetal Neonatal Ed 2000; 83: F101–3

    Article  PubMed  CAS  Google Scholar 

  105. Sacchetti A, Ramoska E, Mcdermott P, et al. ICU use in acute pulmonary edema: does ED management matter? [abstract]. Ann Emerg Med 1997; 30: 430

    Google Scholar 

  106. AMA Department of Drugs. AMA drug evalautions. 5th ed. Chicago (IL): American Medical Association, 1983

    Google Scholar 

  107. Withington DE, Patrick JA, Reynolds F. Histamine release by morphine and diamorphine in man. Anaesthesia 1993; 48: 26–9

    Article  PubMed  CAS  Google Scholar 

  108. Fahmy NR, Sunder N, Soter NA. Role of histamine in the hemodynamic and plasma catecholamine to morphine. Clin Pharmacol Ther 1983; 5: 615–20

    Article  Google Scholar 

  109. Rosow CE, Moss J, Philbin DM. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982; 56: 93–6

    Article  PubMed  CAS  Google Scholar 

  110. Flacke JW, Flacke WE, Bloor BC, et al. Histamine release by four narcotics: a double-blind study in humans. Anesth Analg 1987; 66: 723–30

    Article  PubMed  CAS  Google Scholar 

  111. Committee on Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1995; 26: 1376–98

    Article  Google Scholar 

  112. Dukes MNG. Meyler’s side effects of drugs. Vol. 9. New York: Excerpta Medica, 1980

    Google Scholar 

  113. Gilman AG, Rall TW, Nies AS, et al., editors. Goodman and Gilman’s: the pharmacological basis of therapeutics. 8th ed. New York: Macmillan Publishing Co, 1990

    Google Scholar 

  114. Schiff L. Disease of the Liver. 3rd ed. Philadelphia (PA): JB Lippincott Company, 1969

    Google Scholar 

  115. Beckman H. Dilemmas in drug therapy. Philadelphia (PA): WB Saunders, 1967

    Google Scholar 

  116. Ball M, McQuay HJ, Moore RA, et al. Renal failure and the use of morphine in intensive care. Lancet 1985; I: 784–6

    Article  Google Scholar 

  117. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991; 47: 13–9

    Article  PubMed  CAS  Google Scholar 

  118. Aronoff GR, Berns JS, Brier ME, et al., editors. Drug prescribing in renal failure. 4th ed. Philadelphia (PA): American College of Physicians, 1999

    Google Scholar 

  119. Anon. FDA safety related drug labeling changes: February 12, 2001. Available from URL: http://www.fda.gov/medwatch/SAFETY/2001/feb01.htm [Accessed 2001 Jun 23]

  120. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treat-ment with captopril or MK-421. J Pharmacol Exp Ther 1982; 220: 63–9

    PubMed  CAS  Google Scholar 

  121. Sweet CS, Gross DM, Arbegast PT, et al. Antihypertensive activity of N-((S)-1-(ethoxycarbonyl)-3-phenylpropyl)-L-ala-pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 1981; 216: 558–66

    PubMed  CAS  Google Scholar 

  122. Vlasses PH, Conner DP, Rotmensch HH, et al. Double-blind comparison of captopril and enalapril in mild to moderate hypertension. J Am Coll Cardiol 1986; 7: 651–60

    Article  PubMed  CAS  Google Scholar 

  123. Gomez HJ, Cirillo VJ, Jones KH. The clinical pharmacology of enalapril. J Hypertens Suppl 1983; 1: 65–70

    PubMed  CAS  Google Scholar 

  124. Gilman AG, Rall TW, Nies AS, et al., editors, Goodman and Gilman’s: the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990

    Google Scholar 

  125. McAreavey D, Robertson JIS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40: 326–45

    Article  PubMed  CAS  Google Scholar 

  126. Gavras H, Biollaz J, Waeber B, et al. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK-421. Lancet 1981; II: 543–7

    Article  Google Scholar 

  127. Dusing R, Kayser G, Wagner S, et al. Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme. Am J Cardiol 1987; 59: 50D–4D

    Article  PubMed  CAS  Google Scholar 

  128. Sugimoto K, Kumagai Y, Tateishi T, et al. Effects on autonomic function of a new angiotensin converting enzyme inhibitor, ramipril. J Cardiovasc Pharmacol 1989; 13Suppl. 3: S40–5

    Article  PubMed  Google Scholar 

  129. Bonaduce D, Petretta M, Morgano G, et al. Effects of converting enzyme inhibition on baroreflex sensitivity in patients with myocardial infarction. J Am Coll Cardiol 1992; 20: 587–93

    Article  PubMed  CAS  Google Scholar 

  130. Ferrario CM, Jaiswal N, Yamamoto K, et al. Hypertensive mechanisms and converting enzyme inhibitors. Clin Cardiol 1991; 14Suppl. IV: IV56–62

    PubMed  CAS  Google Scholar 

  131. Vlasses PH, Larijani GE, Conner DP, et al. Enalapril, a non-sulfhydryl angiotensin-converting enzyme inhibitor. Clin Pharm 1985; 4: 27–40

    PubMed  CAS  Google Scholar 

  132. Pitt B. Angiotensin-converting inhibitors in patients with congestive heart failure: a class effect? Am J Cardiol 1991; 68: 106–8

    Article  PubMed  CAS  Google Scholar 

  133. Francis GS. Vasodilators and inotropic agents in the treatment of congestive heart failure. Semin Nephrol 1994; 14: 464–78

    PubMed  CAS  Google Scholar 

  134. Boldt J, Knothe C, Schindler F, et al. Isolated circulatory response to intravenous administration of the ACE inhibitor enalaprilat. Br J Clin Pharmacol 1994; 37: 341–6

    Article  PubMed  CAS  Google Scholar 

  135. Boldt J, Menges T, Wollbruck M, et al. Cardiopulmonary actions of intravenously administered enalaprilat in trauma patients. Crit Care Med 1994; 22: 960–4

    Article  PubMed  CAS  Google Scholar 

  136. Gonzalez-Fernandez RA, Altieri PI, Jimenez R, et al. Effects of enalaprilat on hemodynamics and ventricular activation duration in hypertensive patients with left ventricular hypertrophy: clinical evidence of improved excitation-contraction coupling with angiotensin converting enzyme inhibition in human hypertension. Am J Hypertens 1993; 6: 570–8

    PubMed  CAS  Google Scholar 

  137. Prasad A, Husain S, Quyyumi AA. Effect of enalapril on nitric oxide activity in coronary artery disease. Am J Cardiol 1999; 84: 1–6

    Article  PubMed  CAS  Google Scholar 

  138. Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999; 34: 983–8

    Article  PubMed  CAS  Google Scholar 

  139. Millar JA, Derkx FHM, McLean K, et al. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol 1982; 14: 347–55

    Article  PubMed  CAS  Google Scholar 

  140. Sturrock ND, Struthers AD. Non-steroidal anti-inflammatory drugs and angiotensive converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function. Br J Clin Pharmacol 1993; 35: 343–8

    Article  PubMed  CAS  Google Scholar 

  141. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83Suppl. 2A: 1A–38A

    Article  Google Scholar 

  142. Udeh EC, Chow MSS. Acute hypertension: an appraisal of new and old pharmacologic agents. Formulary 1996; 31: 1178–1179, 1183–1184, 1192–1194, 1197–8

    Google Scholar 

  143. Anon. Drugs for hypertensive emergencies. Med Lett Drugs Ther 1989; 31: 32–4

    Google Scholar 

  144. Mason J, Young P, Freemantle N, et al. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. BMJ 2000; 321: 1113–6

    Article  PubMed  CAS  Google Scholar 

  145. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in procine brain. Nature 1988; 332: 78–81

    Article  PubMed  CAS  Google Scholar 

  146. Waldman SA, Rapaport RM, Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissue. J Biol Chem 1984; 259: 14332–4

    PubMed  CAS  Google Scholar 

  147. Winquist RJ, Faison EP, Waldman SA, et al. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci U S A 1984; 81: 7661–4

    Article  PubMed  CAS  Google Scholar 

  148. Mcgregor A, Richards M, Espiner E, et al. Brain natriuretic peptide administered to man: actions and metabolism. J Clin Endocrinol Metab 1990; 70: 1103–7

    Article  PubMed  CAS  Google Scholar 

  149. De Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science 1985; 230: 767–70

    Article  PubMed  Google Scholar 

  150. Laragh JH. Atrial natriuretic hormone, the renin aldosterone axis, and blood pressure-electrolyte homeostasis. N Engl J Med 1985; 313: 1330–40

    Article  PubMed  CAS  Google Scholar 

  151. Ballerman BJ, Brehner BM. Role of atrial peptides in body fluid homeostasis. Circ Res 1986; 58: 619–30

    Article  Google Scholar 

  152. Kamabayashi Y, Nakao K, Kimura H, et al. Biologic characterization of human brain natriuretic peptide (NESIRITIDE) and rat NESIRITIDE: actions and metabolism. Biochem Biophys Res Commun 1990; 173: 599–605

    Article  Google Scholar 

  153. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91–6

    Article  PubMed  CAS  Google Scholar 

  154. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991; 84: 1551–8

    Article  Google Scholar 

  155. Hobbs RE, Miller LW, Bott-Silverman C, et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 78: 896–901

    Article  PubMed  CAS  Google Scholar 

  156. Burnett Jr JC, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231: 1145–7

    Article  PubMed  Google Scholar 

  157. Rodeheffer RJ, Tanaka I, Imada T, et al. Atrial pressure and secretion of atrial natriuretic factor into the human central circulation. J Am Coll Cardiol 1986; 8: 18–26

    Article  PubMed  CAS  Google Scholar 

  158. Lazzeri C, La Villa G, Bisi G, et al. Cardiovascular function during brain natriuretic peptide during infusion in man. Cardiology 1995; 86: 396–401

    Article  PubMed  CAS  Google Scholar 

  159. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 1999; 34: 155–62

    Article  PubMed  CAS  Google Scholar 

  160. La Villa G, Stefani L, Lazzeri C, et al. Acute effects of physiological increments of brain natriuretic peptide in humans. Hypertension 1995; 26: 628–33

    Article  PubMed  Google Scholar 

  161. La Villa G, Bisi G, Lazzeri C, et al. Cardiovascular effects of brain natriuretic peptide in essential hypertension. Hypertension 1995; 25: 1053–7

    Article  PubMed  Google Scholar 

  162. Lainchbury JG, Richard AM, Nicholls MG, et al. The effect of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. 1997; 30(3): 398–404

    CAS  Google Scholar 

  163. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002 287;12:1531–40

    Article  Google Scholar 

  164. Colucci WS, Elkayam U, Horton DP, Nesiritide Study Group, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343: 246–53

    Article  PubMed  CAS  Google Scholar 

  165. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001; 88: 35–9

    Article  PubMed  CAS  Google Scholar 

  166. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94: 3184–9

    Article  PubMed  CAS  Google Scholar 

  167. Natrecor® [prescribing information]. Sunnyvale (CA): Scios Inc., 2001

  168. Yanagisawa M, Kurihara H, Kurihara S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–5

    Article  PubMed  CAS  Google Scholar 

  169. Inoue A, Yanagisawa M, Takuwa Y, et al. The human perpeoendothelin-1 gene: complete nucleotide sequence and regulation of expression. J Biol Chem 1989; 264: 14954–9

    PubMed  CAS  Google Scholar 

  170. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides. Proc Natl Acad Sci U S A 1989; 86: 2863–7

    Article  PubMed  CAS  Google Scholar 

  171. Sumner MJ, Cannon TR, Mundin JW, et al. Endothelin ETA and ETB receptors mediate vascular smooth muscle cell contraction. Br J Pharmacol 1992; 107: 858–60

    Article  PubMed  CAS  Google Scholar 

  172. Yang Z, Bauer E, von Segesser L, et al. F. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol 1990; 16: 654–60

    Article  PubMed  CAS  Google Scholar 

  173. Kiowski W, Lüscher TF, Linder L, et al. Endothelin-1-induced vasoconstriction in humans: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991; 83: 469–75

    Article  PubMed  CAS  Google Scholar 

  174. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97: 752–6

    Article  PubMed  CAS  Google Scholar 

  175. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with congestive heart failure. Circulation 1992; 85: 504–9

    Article  PubMed  CAS  Google Scholar 

  176. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580–6

    Article  PubMed  CAS  Google Scholar 

  177. Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997; 18: 254–8

    Article  PubMed  CAS  Google Scholar 

  178. Fraccarollo D, Hu K, Galuppo P, et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction. Circulation 1997; 96: 3963–73

    Article  PubMed  CAS  Google Scholar 

  179. Mishima T, Tanimura M, Suzuki G, et al. Effects of long term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000; 35: 222–9

    Article  PubMed  CAS  Google Scholar 

  180. Clozel M, Qiu C, Qiu CS, et al. Short term endothelin receptor blockade with tezosentan has both immediate and long term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 2002; 39: 142–7

    Article  PubMed  CAS  Google Scholar 

  181. Nguyen QT, Cernacek P, Calderoni A, et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998; 98: 2323–30

    Article  PubMed  CAS  Google Scholar 

  182. Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001; 103: 973–80

    Article  PubMed  CAS  Google Scholar 

  183. Lyford J. Selected Highlights from the 50th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, 2001. Curr Control Trials Cardiovasc Med 2001; 2(2): 85–9

    Article  PubMed  Google Scholar 

  184. Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996; 60: 124–37

    Article  PubMed  CAS  Google Scholar 

  185. Breu V, Ertel SI, Roux S, et al. The pharmacology of bosentan. Exp Opin Invest Drugs 1998; 7: 1173–92

    Article  CAS  Google Scholar 

  186. Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732–6

    Article  PubMed  CAS  Google Scholar 

  187. Packer M. Multicenter, double-blind, placebo-controlled study of long term endothelin blockade with bosentan in chronic heart failure: results of the REACH-1 trial [abstract]. Circulation 1998; 98(17): I–3

    Google Scholar 

  188. Hirata Y, Takagi Y, Fukuda Y, et al. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225–8

    Article  PubMed  CAS  Google Scholar 

  189. Seo B, Oemar BS, Siebenmann R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89: 1203–8

    Article  PubMed  CAS  Google Scholar 

  190. Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94: 1578–84

    Article  PubMed  CAS  Google Scholar 

  191. Wada A, Tsutamoto T, Fukai D, et al. Comparison of the effects of selective endothelin ETA- and ETB-receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997; 30: 1385–92

    Article  PubMed  CAS  Google Scholar 

  192. Dupuis J, Rouleau JL, Cernacek P. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation 1998; 98: 1684–7

    Article  PubMed  CAS  Google Scholar 

  193. Spieker LE, Mitrovic V, Noll G, et al. Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure. ET 003 investigators. J Am Coll Cardiol 2000; 35: 1745–52

    Article  PubMed  CAS  Google Scholar 

  194. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000; 101: 2922–7

    Article  PubMed  CAS  Google Scholar 

  195. Clozel M, Ramuz H, Clozel J-P, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999; 290(2): 840–6

    PubMed  CAS  Google Scholar 

  196. Wilhelm SM, Stowe NT, Robinson AV, et al. The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function. Transplantation 2001; 71: 211–6

    Article  PubMed  CAS  Google Scholar 

  197. Schalcher C, Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 2001; 142: 340–9

    Article  PubMed  CAS  Google Scholar 

  198. Cotter G, Kiowski W, Kaluski E, et al. Tezosentan (the first IV endothelin receptor A/B antagonist) reduces peripheral resistance and increases myocardial contractility despite reducing left ventricular filling (wedge) pressure in patients with congestive heart failure [abstract P1649]. Eur Heart J 2000; 21:297

    Google Scholar 

  199. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988; I: 1088–92

    Article  Google Scholar 

  200. Flaherty JT. Comparison of intravenous nitroglycerin and sodium nitroprusside in acute myocardial infarction. Am J Med 1983; 74: 53–60

    Article  PubMed  CAS  Google Scholar 

  201. Loh E, Elkayam U, Cody R, et al. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail 2001; 7(2): 115–21

    Google Scholar 

  202. Biddle TL, Benotti JR, Creager MA, et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol 1987; 59: 1345–50

    Article  PubMed  CAS  Google Scholar 

  203. Mager G, Klocke RK, Kux A, et al. Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J 1991; 121: 1974–83

    Article  PubMed  CAS  Google Scholar 

  204. Grose R, Strain J, Greenberg M, et al. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 1986; 7: 1107–13

    Article  PubMed  CAS  Google Scholar 

  205. Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patients responsiveness. Circulation 1986; 73Suppl. III: 175–83

    Google Scholar 

  206. Monrad ES, Baim DS, Smith HS, et al. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 1986; 73Suppl. III: 168–74

    Google Scholar 

  207. Marcus RH, Raw K, Patel J, et al. Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 66: 1107–12

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Carle Foundation Hospital, University of Illinois College of Medicine at Urbana-Champaign, 611 W University Ave, Urbana, Illinois, 61801, USA

    Kourosh Moazemi, Jatinder S. Chana, Anna Marie Willard &  Abraham G. Kocheril

Authors
  1. Kourosh Moazemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jatinder S. Chana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Marie Willard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abraham G. Kocheril
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abraham G. Kocheril.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moazemi, K., Chana, J.S., Willard, A.M. et al. Intravenous Vasodilator Therapy in Congestive Heart Failure. Drugs Aging 20, 485–508 (2003). https://doi.org/10.2165/00002512-200320070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320070-00002

Keywords

Search

Navigation